A piece in The Economist deals with the negative information coming out in Johnson & Johnson’s trial over ASR hip implants manufactured by its subsidiary, DePuy Orthopaedics.
“Most companies do everything they can to keep their executives away from court,” the piece states. “A case in California helps to demonstrate why.”
Studies have shown nearly half of the implants break down and ...
continue reading...
In a bipartisan effort, U.S. Senators have reintroduced legislation banning a pharmaceutical industry practice that keeps lower-cost medications away from patients who need them. The practice, commonly called “pay for delay,” occurs when one drug company pays another to delay introducing a less-expensive generic version of a medication.
According to Reuters, both American and European anti-trust regulators have long criticized the practice. It recently came to the forefront again after European ...
continue reading...
In a Los Angeles Superior Court trial, an occupational medicine specialist testified that a man’s artificial hip had to be removed because of “toxic exposure” from metal debris that the implant was shedding, according to a Reuters story.
Plaintiff Loren Kransky’s is the first of more than 10,000 U.S. lawsuits about the implants to go to trial.
The artificial hips, made by Johnson & Johnson subsidiary DePuy Orthopedics, feature both a ball ...
continue reading...
A story in the Philadelphia Inquirer says more than 6,000 federal lawsuits have been filed against some of the biggest manufacturers of pelvic mesh implants. Plaintiffs claim that the devices have caused medical problems including infections and chronic pain.
The story includes an interview with a patient named Susan Harrison, a kindergarten assistant who had to miss a lot of work when she suffered a string of ...
continue reading...
European regulators are accusing Johnson & Johnson of illegally paying another company to delay the availability of a generic version of a product – in the process denying cancer patients access to a less expensive source of a drug that eases severe pain.
According to a story in the New York Times, the product at issue is a transdermal patch used to deliver the drug fentanyl through the skin. Antitrust authorities ...
continue reading...According to a story on The Motley Fool, Johnson & Johnson-owned Ethicon announced in a press release that the U.S. Food and Drug Administration has granted approval for a tissue sealer called Enseal G 2.
The story characterizes it as “a bit of bright news” from Ethicon, noting that the company has initiated a number of recalls lately for items including hemorrhoidal staples and wound products.
And Ethicon is currently on trial ...
continue reading...
